Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Net Income (Continuing Operations) : $-46.22 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Paradigm Biopharmaceuticals's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was $-32.77 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.22 Mil.

Paradigm Biopharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Net Income (Continuing Operations) Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-10.85

-8.49

-26.22

-27.58

-34.84

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial												-19.30	-8.62	-21.50	-13.45	-32.77

Paradigm Biopharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-46.22 Mil.

Paradigm Biopharmaceuticals (OTCPK:PBIGF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Paradigm Biopharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).